Inhibitors of the PLK1 polo-box domain: drug design strategies and therapeutic opportunities in cancer
Author:
Affiliation:
1. Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, USA
Funder
The authors are funded by the University of South Carolina and the National Institutes of Health
Publisher
Informa UK Limited
Subject
Drug Discovery
Link
https://www.tandfonline.com/doi/pdf/10.1080/17460441.2023.2159942
Reference119 articles.
1. Playing polo during mitosis: PLK1 takes the lead
2. Polo-Like Kinases (Plks), a Key Regulator of Cell Cycle and New Potential Target for Cancer Therapy
3. Polo-like kinases
4. Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy
5. Molecular dynamics of PLK1 during mitosis
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Recent developments in two-dimensional molybdenum disulfide-based multimodal cancer theranostics;Journal of Nanobiotechnology;2024-08-28
2. Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas;Cell Death & Disease;2024-07-22
3. Progress with polo-like kinase (PLK) inhibitors: a patent review (2018–present);Expert Opinion on Therapeutic Patents;2024-07-15
4. Auranofin and reactive oxygen species inhibit protein synthesis and regulate the level of the PLK1 protein in Ewing sarcoma cells;Frontiers in Oncology;2024-06-12
5. Auranofin and reactive oxygen species inhibit protein synthesis and regulate the level of the PLK1 protein in Ewing sarcoma cells;2024-05-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3